https://socratec-pharma.de/publications/randomized-trial-of-the-efficacy-and-safety-of-a-new-oral-spray-for-drug-induced-xerostomia2016-08-16T11:32:30+02:00https://socratec-pharma.de/publications/the-influence-of-hydroxypropyl-methylcellulose-hpmc-molecular-weight-concentration-and-effect-of-food-on-in-vivo-erosion-behavior-of-hpmc-matrix-tablets2020-10-30T15:31:50+01:00https://socratec-pharma.de/publications/gastrointestinal-erosion-behavior-of-magnetically-marked-gel-matrix-tablets2020-10-30T15:35:57+01:00https://socratec-pharma.de/publications/bioavailability-and-pharmacodynamics-of-two-10-mg-estradiol-valerate-depot-formulations-following-im-single-dose-administration-in-healthy-postmenopausal-volunteers2020-10-30T15:36:32+01:00https://socratec-pharma.de/publications/harmonization-of-regulatory-approaches-for-evaluating-therapeutic-equivalence-and-interchangeability-of-multisource-drug-products-workshop-summary-report2015-08-13T11:44:33+02:00https://socratec-pharma.de/publications/the-influence-of-propiverine-hydrochloride-on-cardiac-repolarization-in-healthy-women-and-cardiac-male-patients2015-08-13T11:44:32+02:00https://socratec-pharma.de/publications/workshopconference-report-on-ema-draft-guideline-on-validation-of-bioanalytical-methods2015-08-13T11:44:31+02:00https://socratec-pharma.de/publications/austausch-von-starken-opioiden-die-therapiaequivalente-arzneimittelqualitaet-muss-gewaehrleistet-sein2015-08-13T11:44:30+02:00https://socratec-pharma.de/publications/pharmacokinetics-immunogenicity-and-bioactivity-of-the-therapeutic-antibody-catumaxomab-intraperitoneally-administered-to-cancer-patients2015-08-13T11:44:29+02:00https://socratec-pharma.de/publications/anforderungen-an-einer-optimierte-opioidtherapie-chronischer-schmerzen-gleichmaessige-plasmaspiegel-versus-chronoadjustierte-analgesie2015-08-13T11:44:28+02:00https://socratec-pharma.de/publications/bedeutung-von-glp-1-fuer-die-glucose-homoeostase2015-08-13T11:44:27+02:00https://socratec-pharma.de/publications/investigation-of-the-tolerability-and-safety-of-film-coated-tablets-containing-ivy-extracts-prospan--cough-tablets-in-the-treatment-of-colds-accompanied-by-coughing2015-08-13T11:44:26+02:00https://socratec-pharma.de/publications/differences-in-bioavailability-between-60mg-of-nifedipine-osmotic-pushpull-systems-after-fasted-and-fed-administration2015-08-13T11:44:25+02:00https://socratec-pharma.de/publications/bioavailabilitybioequivalence-requirements-of-immediate-release-products-resolutions-and-issues2015-08-13T11:44:24+02:00https://socratec-pharma.de/publications/fentanyl-formulations-for-the-management-of-pain-a-review2015-08-13T11:44:23+02:00https://socratec-pharma.de/publications/phenotyping-with-sulfasalazine-time-dependence-and-relation-to-nat2-pharmacogenetics2015-08-13T11:44:22+02:00https://socratec-pharma.de/publications/characterization-of-the-behavior-of-alginate-based-microcapsules-in-vitro-and-in-vivo2015-08-13T11:44:21+02:00https://socratec-pharma.de/publications/nifedipin-retardtabletten-mit-unterschiedlicher-galenik2015-08-13T11:44:20+02:00https://socratec-pharma.de/publications/magnetic-marker-monitoring-high-resolution-real-time-tracking-of-oral-solid-dosage-forms-in-the-gastroinestinal-tract2015-08-13T11:44:19+02:00https://socratec-pharma.de/publications/nifedipin-retardtabletten-mit-unterschiedlicher-galenik2015-08-13T11:44:18+02:00https://socratec-pharma.de/publications/characterisation-of-gastric-residence-time-of-provide-xtra-drink-in-healty-volunteers2015-08-13T11:44:17+02:00https://socratec-pharma.de/publications/characterization-of-the-behavior-of-alginate-based-microcapsules-in-vitro-and-in-vivo2015-08-13T11:44:16+02:00https://socratec-pharma.de/publications/significance-of-the-biopharmaceutical-properties-of-tramadol-sustained-release-formulations-for-chrono-pharmacologically-optimized-treatment-of-pain-from-various-sources2015-08-13T11:44:15+02:00https://socratec-pharma.de/publications/characterisation-of-gastric-residence-time-of-providextra-drink-in-healthy-volunteers2015-08-13T11:44:14+02:00https://socratec-pharma.de/publications/gcp-standards-in-klinischen-studien-mit-medizinprodukten-chance-oder-hindernis2015-08-13T11:44:13+02:00https://socratec-pharma.de/publications/biomarkers-and-coagulation-tests-for-assessing-the-biosimilarity-of-a-generic-low-molecular-weight-heparin-results-of-a-study-in-healthy-subjects-with-enoxaparin2015-08-13T11:44:12+02:00https://socratec-pharma.de/publications/schneller-am-ziel-mit-magnetic-marker-monitoring2015-08-13T11:44:11+02:00https://socratec-pharma.de/publications/importance-of-the-formulation-for-a-chronopharmacologically-optimised-way-of-pain-therapy-results-of-a-comparative-bioavailability-study-of-tramadol-extended-release-capsules-after-single-dose-evening2015-08-13T11:44:10+02:00https://socratec-pharma.de/publications/bedeutung-der-galenik-in-der-chrono-adjustierten-schmerzbehandlung2015-08-13T11:44:09+02:00https://socratec-pharma.de/publications/comparison-of-two-marketed-nifedipine-modified-release-formulations-an-exploratory-clinical-food-interaction-study2015-08-13T11:44:08+02:00https://socratec-pharma.de/publications/gastro-intestinal-transit-of-enteric-coated-mesalazine-products-magnetic-marker-monitoring2015-08-13T11:44:07+02:00https://socratec-pharma.de/publications/lack-of-a-pharmacokinetic-interaction-between-steady-state-roflumilast-and-single-dose-midazolam-in-healthy-subjects-22019-05-08T11:39:46+02:00https://socratec-pharma.de/publications/magnetic-monitoring-as-a-diagnostic-method-for-investigating-motility-in-the-human-digestive-system2015-08-13T11:44:05+02:00https://socratec-pharma.de/publications/gastrointestinal-tolerance-of-a-high-energy-oral-nutritional-supplement-ons-in-healthy-elderly-and-dialysis-patients2015-08-13T11:44:04+02:00https://socratec-pharma.de/publications/lidocaine-8-mg-sore-throat-lozenges-in-the-treatment-of-acute-pharyngitis2015-08-13T11:44:03+02:00https://socratec-pharma.de/publications/gastro-intestinal-transit-of-solid-oral-dosage-forms-imaging-studies-using-magnetic-marker-monitoring-technique2015-08-13T11:44:02+02:00https://socratec-pharma.de/publications/pharmacokinetic-drug-interaction-profiles-of-proton-pump-inhibitors2015-08-13T11:44:01+02:00https://socratec-pharma.de/publications/pseudo-current-density-maps-of-electrophysiological-heart-nerve-or-brain-function-and-their-physical-basis2015-08-13T11:44:00+02:00https://socratec-pharma.de/publications/lack-of-a-pharmacokinetic-interaction-between-steady-state-roflumilast-and-single-dose-midazolam-in-healthy-subjects2015-08-13T11:43:59+02:00https://socratec-pharma.de/publications/significant-food-interactions-observed-with-a-nifedipine-modified-release-formulation-marketed-in-the-european-union2015-08-13T11:43:58+02:00https://socratec-pharma.de/publications/neue-richtlinien-fuer-die-beurteilung-der-bioverfuegbarkeit-bioaequivalenz2015-08-13T11:43:57+02:00https://socratec-pharma.de/publications/charakterisierung-der-magenentleerung-einer-proteinhydrolysathaltigen-kohlenhydratreichen-trinknahrung-im-vergleich-zu-einer-kohlenhydratreichen-referenznahrung2015-08-13T11:43:56+02:00https://socratec-pharma.de/publications/felodipine-quantification-in-human-plasma-by-high-performance-liquid-cromatography-coupled-to-tandem-mass-spectrometry2015-08-13T11:43:55+02:00https://socratec-pharma.de/publications/lack-of-pharmacokinetic-interaction-between-roflumilast-and-midazolam2015-08-13T11:43:54+02:00https://socratec-pharma.de/publications/wie-die-arzneiform-zum-therapieerfolg-beitraegt-arzneizubereitungen-mit-calciumkanal-blockern2015-08-13T11:43:53+02:00https://socratec-pharma.de/publications/gastric-emptying-and-gastric-residual-volume-after-intake-of-a-sip-feed-containing-carbohydrates-and-protein-hydrolysate2015-08-13T11:43:52+02:00https://socratec-pharma.de/publications/determination-of-hyperforin-in-mouse-brain-by-high-performance-liquid-chromatographytandem-mass-spectrometry2015-08-13T11:43:51+02:00https://socratec-pharma.de/publications/pharmacokinetics-and-bioavailability-of-denaverine-hydrochloride-in-healthy-subjects-following-intravenous-oral-and-rectal-single-doses2015-08-13T11:43:50+02:00https://socratec-pharma.de/publications/nsar-konzepte-zur-galenischen-optimierung2015-08-13T11:43:49+02:00https://socratec-pharma.de/publications/sind-nifedipin-retardpraeparate-austauschbar2015-08-13T11:43:48+02:00https://socratec-pharma.de/publications/pharmaceutical-quality-of-different-ginkgo-biloba-brands2015-08-13T11:43:47+02:00https://socratec-pharma.de/publications/sensitive-and-specific-liquid-chromatographic-tandem-mass-spectrometric-assay-for-dihydroergotamine-and-its-major-metabolite-in-human-plasma2015-08-13T11:43:46+02:00https://socratec-pharma.de/publications/determination-of-11-keto-boswellic-acid-in-human-plasma2015-08-13T11:43:45+02:00https://socratec-pharma.de/publications/influence-of-pharmaceutical-quality-on-the-bioavailability-of-active-components-form-ginkgo-biloba-preparations2015-08-13T11:43:44+02:00https://socratec-pharma.de/publications/the-effect-of-food-on-the-pharmacokinetics-of-nifedipine-in-two-slow-release-formulations-pronounced-lag-time-after-a-high-fat-breakfast2015-08-13T11:43:43+02:00https://socratec-pharma.de/publications/formulation-dependent-food-effects-demonstrated-for-nifedipine-modified-release-preparations-marketed-in-the-european-union2015-08-13T11:43:42+02:00https://socratec-pharma.de/publications/dosage-form-related-food-interaction-observed-in-a-marketed-one-daily-nifedipine-formulation-after-a-high-fat-american-breakfast2015-08-13T11:43:41+02:00https://socratec-pharma.de/publications/nsar-konzepte-zur-galenischen-optimierung2015-08-13T11:43:40+02:00https://socratec-pharma.de/publications/sind-nifedipin-retardpraeparate-austauschbar2015-08-13T11:43:39+02:00https://socratec-pharma.de/publications/qualitaet-von-omeprazol-praeparaten2015-08-13T11:43:38+02:00https://socratec-pharma.de/publications/simultaneous-determination-of-flupirtine-and-its-major-active-metabolite-in-human-plasma-by-liquid-chromatography-tandem-mass-spectrometry2015-08-13T11:43:37+02:00https://socratec-pharma.de/publications/product-related-food-effects-for-nifedipine-once-daily-solid-oral-dosage-forms2015-08-13T11:43:36+02:00https://socratec-pharma.de/publications/biopharmaceutical-characterisation-of-herbal-medicinal-products-are-in-vivo-studies-necessary2015-08-13T11:43:35+02:00https://socratec-pharma.de/publications/qualitaet-von-eisenpraeparaten2015-08-13T11:43:34+02:00https://socratec-pharma.de/publications/the-biopharmaceutics-classification-system-bcs-class-iii-drugs-better-candidates-for-babe-waiver2015-08-13T11:43:33+02:00https://socratec-pharma.de/publications/dose-proportionality-of-oral-thioctic-acid-coincidence-of-assessments-via-pooled-plasma-and-individual-data2015-08-13T11:43:32+02:00https://socratec-pharma.de/publications/lack-of-interaction-between-thioctic-acid-glibenclamide-and-acarbose2015-08-13T11:43:31+02:00https://socratec-pharma.de/publications/bioequivalence-study-of-two-morphine-extended-release-formulations-after-multiple-dosing-in-healthy-volunteers2015-08-13T11:43:30+02:00https://socratec-pharma.de/publications/bioavailability-and-selected-pharmacokinetic-parameters-of-clindamycin-hydrochloride-after-administration-of-a-new-600-mg-tablet-formulation2015-08-13T11:43:29+02:00https://socratec-pharma.de/publications/qualitaet-von-eisenpraeparaten-sind-bioverfuegbarkeitspruefungen-erforderlich2015-08-13T11:43:28+02:00https://socratec-pharma.de/publications/bcs-wegweiser-bei-phytopharmaka2015-08-13T11:43:27+02:00https://socratec-pharma.de/publications/klinische-studien-92015-08-13T11:43:26+02:00https://socratec-pharma.de/publications/klinische-studien-102015-08-13T11:43:25+02:00https://socratec-pharma.de/publications/trough-concentrations-as-parameter-for-the-autoinduction-of-carbamazepine-during-repetitive-oral-administrations2015-08-13T11:43:24+02:00https://socratec-pharma.de/publications/planung-durchfuehrung-und-auswertung-klinischer-studien2015-08-13T11:43:23+02:00https://socratec-pharma.de/publications/gender-effect-on-the-pharmacokinetics-of-thioctic-acid-an-evaluation-of-several-bioavailability-studies2015-08-13T11:43:22+02:00https://socratec-pharma.de/publications/das-biopharmazeutische-klassifizierungssystem-bcs-neuer-ansatz-bei-der-beurteilung-von-arzneimitteln2015-08-13T11:43:21+02:00https://socratec-pharma.de/publications/bioavailability-study-of-two-carbamazepine-containing-sustained-release-formulations-after-multiple-oral-dose-administration2015-08-13T11:43:20+02:00https://socratec-pharma.de/publications/absolute-bioavailability-of-two-oral-dantrolene-formulations2015-08-13T11:43:19+02:00https://socratec-pharma.de/publications/relative-bioavailability-of-etilefrine-from-different-galenical-formulations2015-08-13T11:43:18+02:00https://socratec-pharma.de/publications/study-of-pharmacokinetic-interaction-of-thioctic-acid-and-metformin2015-08-13T11:43:17+02:00https://socratec-pharma.de/publications/vergleichende-untersuchung-von-fsh-produkten2015-08-13T11:43:16+02:00https://socratec-pharma.de/publications/zur-qualitaet-von-bluttests-in-apotheken2015-08-13T11:43:15+02:00https://socratec-pharma.de/publications/sulfonylureas-physico-chemical-properties-analytical-methods-of-determination-and-bioavailability2015-08-13T11:43:14+02:00https://socratec-pharma.de/publications/bioavailability-bioeqivalence-requirements-of-immediate-release-products-resolutions-and-issues2015-08-13T11:43:13+02:00https://socratec-pharma.de/publications/influence-of-food-on-the-bioavailability-of-controlledmodified-release-products-in-kuhlmann-j-weihrauch-tr-eds2015-08-13T11:43:12+02:00https://socratec-pharma.de/publications/bioverfuegbarkeit-von-rytmonorm-importen2015-08-13T11:43:11+02:00https://socratec-pharma.de/publications/influence-of-food-intake-on-the-bioavailability-of-alpha-lipoic-acid2015-08-13T11:43:10+02:00https://socratec-pharma.de/publications/influence-of-food-intake-on-the-bioavailability-of-thioctic-acid-enantiomers2015-08-13T11:43:09+02:00https://socratec-pharma.de/publications/enantioselective-pharmacokinetics-and-bioavailability-of-diprafenone-in-healthy-volunteers2015-08-13T11:43:08+02:00https://socratec-pharma.de/publications/drug-interactions-in-the-gastrointestinal-tract-and-their-impact-on-drug-absorption-and-systemic-availability-a-mechanistic-review2015-08-13T11:43:07+02:00https://socratec-pharma.de/publications/single-and-multiple-dose-administration-of-alpha-lipoic-acid-in-a-replicate-study-design2015-08-13T11:43:06+02:00https://socratec-pharma.de/publications/bioequivalence-of-highly-variable-drugs-and-drug-products-steady-state-studies2015-08-13T11:43:05+02:00https://socratec-pharma.de/publications/possibilities-and-limitations-on-the-interpretation-of-pharmacokinetic-interaction-studies-drug-drug-drug-food2015-08-13T11:43:04+02:00https://socratec-pharma.de/publications/practical-strategies-and-design-advantages-in-highly-variable-drug-studies-multiple-dose-and-replicate-administration-design2015-08-13T11:43:03+02:00https://socratec-pharma.de/publications/comparison-of-the-bioavailabilities-of-erythromycin-estolate-and-erythromycin-ethylsuccinate-dry-suspension-preparations-in-steady-state2015-08-13T11:43:02+02:00https://socratec-pharma.de/publications/vergleich-von-erythromycinestolat-und-erythromycinethylsuccinat2015-08-13T11:43:01+02:00https://socratec-pharma.de/publications/in-vitro-und-in-vivo-untersuchungen-zu-den-biopharmazeutischen-eigenschaften-zweier-kombinationsanalgetika2015-08-13T11:43:00+02:00https://socratec-pharma.de/publications/influence-of-chloroquine-and-other-substances-on-the-collagenolytic-activity-in-human-osteoarthritic-cartilage-in-vitro2015-08-13T11:42:59+02:00https://socratec-pharma.de/publications/advantages-of-a-steady-state-crossover-design-in-assessment-of-biorquivalence-of-highly-variable-drugs-propafenone2015-08-13T11:42:58+02:00https://socratec-pharma.de/publications/bio-international-1994-wichtige-ergebnisse2015-08-13T11:42:57+02:00https://socratec-pharma.de/publications/human-recombinant-interleukin-1-alpha-and-beta-and-articular-tissue-integrity-an-in-vivo-study-on-hens-and-rats2015-08-13T11:42:56+02:00https://socratec-pharma.de/publications/beeinflussung-der-aktivitaet-von-kollagenasen-durch-verschiedene-antirheumatische-wirkstoffe2015-08-13T11:42:55+02:00https://socratec-pharma.de/publications/nsaids-drug-group-woth-relevant-need-for-galenic-improvement2017-01-31T10:35:09+01:00https://socratec-pharma.de/publications/new-high-protein-and-high-energy-oral-nutritional-supplement-for-compliance-and-tolerance-in-elderly-care2020-10-29T15:13:57+01:00https://socratec-pharma.de/publications/dispensing-a-high-caloric-high-protein-oral-nutritional-supplement-3-times-daily-is-well-tolerated-and-increase-compliance-in-elderly2020-10-29T15:16:38+01:00https://socratec-pharma.de/publications/the-global-bioequivalence-harmonization-initiative-summary-report-for-eufeps-international-conference2020-10-29T15:29:58+01:00https://socratec-pharma.de/publications/regorafenib-first-in-human-as-eye-drops2020-10-30T15:43:35+01:00https://socratec-pharma.de/publications/pharmacokinetics-and-pharmacodynamics-of-three-dosages-of-oestriol-after-continuous-vaginal-ring-administration-for-21-days-in-healthy-postmenopausal-women2020-10-29T15:33:23+01:00https://socratec-pharma.de/publications/vericiguat-nitroglycerin-clinical-interaction-venice-a-phase-1-multicenter-randomized-placebo-controlled-double-blind-group-comparison-study-in-patients-with-stable-coronary-artery-disease-to-e2020-10-29T15:22:15+01:00https://socratec-pharma.de/publications/pain-relief-of-sore-throat-with-a-new-anti-inflammatory-throat-lozenge-ibuprofen-25-mg-a-randomised-double-blind-placebo-controlled-international-phase-iii-study2020-10-29T15:25:06+01:00https://socratec-pharma.de/publications/efficacy-of-b-mg-lidocaine-and-2-mg-cetylpyridinium-chloride-cpc-fixedcombination-lozenges-on-sore-throat-pain-intensity-compared-with-1-mg-lidocaine-and-2-mg-cpc-fixed-combination-lozenges-in-subje2020-10-29T15:26:05+01:00https://socratec-pharma.de/publications/eacpt-1298-tolerability-and-blood-pressure-effects-of-a-long-acting-nitrate-co-administered-with-vericiguat-results-of-the-vericiguat-isosorbide-mononitrate-interaction-visor-study2020-10-29T15:35:00+01:00https://socratec-pharma.de/publications/pharmacodynamic-effects-of-the-vericiguat-isosorbide-mononitrate-interaction-visor-study-in-stable-cad-patients2020-10-29T15:19:33+01:00https://socratec-pharma.de/publications/lidocaine-8-mg-sore-throat-lozenges-in-the-treatment-of-acute-pharyngitis-22019-05-08T11:29:04+02:00https://socratec-pharma.de/publications/the-global-bioequivalence-harmonisation-initiative-report-of-eufeps-aaps-third-conference2020-05-28T19:01:14+02:00https://socratec-pharma.de/publications/inhibition-of-ovulation-during-co-administration-of-the-once-daily-oral-gonadotropin-releasing-hormone-receptor-antagonist-relugolix-with-estradiol-and-norethindrone-acetate-in-healthy-premenopausa2020-10-29T15:38:23+01:00https://socratec-pharma.de/publications/a-novel-rizatriptan-oral-gel-formulation-bioavailability-and-bioequivalence2020-10-30T14:51:57+01:00https://socratec-pharma.de/publications/a-randomized-open-label-crossover-study-evaluating-bioequivalence-of-two-n-acetylcysteine-2-oral-solution-formulations-in-healthy-subjects2020-10-30T15:01:17+01:00https://socratec-pharma.de/publications/evaluation-of-the-warming-sensation-acceptability-and-local-tolerability-of-an-acetylcysteine-oral-solution-containing-the-flavoring-agent-iff-flavor-316282-in-the-treatment-of-productive-cough2020-10-30T15:04:23+01:00https://socratec-pharma.de/publications/who-is-a-healthy-subject-consensus-results-on-pivotal-eligibility-criteria-for-clinical-trials2020-10-30T15:07:06+01:00https://socratec-pharma.de/publications/relative-bioavailability-of-a-newly-developed-5-mg-levomethadone-hydrochloride-ir-tablet-l-polamidon-5-mg-tablets-in-comparison-with-the-5-mg-levomethadone-hydrochloride-oral-solution-l-polam2020-10-30T15:25:37+01:00https://socratec-pharma.de/publications/pharmacokinetic-drug-interaction-profiles-of-proton-pump-inhibitors-an-update2020-10-30T15:31:59+01:00https://socratec-pharma.de/publications/observational-study-on-the-tolerability-and-safety-of-film-coated-tablets-containing-ivy-extract-prospan-cough-tablets-in-the-treatment-of-colds-accompanied-by-coughing2020-10-30T15:38:00+01:00https://socratec-pharma.de/publications/electrophysiological-profile-of-propiverine-relationship-to-cardiac-risk2020-11-06T14:19:18+01:00https://socratec-pharma.de/publications/theranostic-pdt-with-the-antibody-anti-isoform-4-sod-mitocondrial-labeled-with-ppix-in-the-lung-cancer-cell-line-a-5492020-11-06T14:23:13+01:00https://socratec-pharma.de/publications/how-to-interpret-an-investigators-brochure-for-meaningful-risk-assessment-results-of-an-agah-discussion-forum2021-02-07T08:41:05+01:00https://socratec-pharma.de/publications/single-dose-pharmacokinetics-and-pharmacodynamics-assessment-of-oestriol-and-trimegestone-containing-vaginal-rings-in-healthy-women-with-childbearing-potential2021-03-02T12:14:06+01:00https://socratec-pharma.de/publications/pharmacokinetics-of-oral-pridinol-results-of-a-randomized-crossover-bioequivalence-trial-in-healthy-subjects2021-07-14T14:17:51+02:00https://socratec-pharma.de/publications/the-global-bioequivalence-harmonisation-initiative-gbhi-report-of-eufeps-aaps-fourth-conference2021-09-16T09:11:31+02:00https://socratec-pharma.de/publications/ovulation-inhibition-with-a-new-vaginal-ring-containing-trimegestone2021-12-17T11:15:58+01:00https://socratec-pharma.de/publications/intravaginal-tolterodine-formulation-intended-for-overactive-bladder-treatment-results-of-a-pharmacokinetic-phase-i-pilot-study-in-healthy-postmenopausal-women2022-02-08T11:39:37+01:00https://socratec-pharma.de/publications/effect-on-ovarian-activity-and-ovulation-inhibition-of-different-oral-dosages-of-levonorgestrel2022-05-11T15:31:32+02:00https://socratec-pharma.de/publications/development-of-a-furosemide-containing-expandable-system-for-gastric-retention2022-11-11T11:23:50+01:00https://socratec-pharma.de/publications/vericiguat-in-combination-with-isosorbide-mononitrate-in-patients-with-chronic-coronary-syndromes-the-randomized-phase-ib-visor-study2022-05-13T11:56:22+02:00https://socratec-pharma.de/publications/vericiguat-in-combination-with-short-acting-nitroglycerin-in-patients-with-chronic-coronary-syndromes-the-randomized-phase-ib-venice-study2022-11-11T11:25:22+01:00https://socratec-pharma.de/publications/investigations-on-dose-proportionality-and-drug-drug-interaction-for-a-fixed-dose-combination-of-trazodone-and-gabapentin2022-11-11T11:21:32+01:00https://socratec-pharma.de/publications/comparative-bioavailability-study-of-a-novel-multi-day-patch-formulation-of-rivastigmine-twice-weekly-with-exelon-transdermal-patch-daily-a-randomized-clinical-trial2022-11-11T11:50:13+01:00https://socratec-pharma.de/publications/bioavailability-study-of-a-transdermal-patch-formulation-of-rivastigmine-compared-with-exelon-in-healthy-subjects2022-11-11T11:50:32+01:00https://socratec-pharma.de/publications/healing-water-leads-to-reduction-of-heartburn-randomised-placebo-controlled-phase-iii-trial-stomach-still2022-11-15T10:05:59+01:00https://socratec-pharma.de/publications/heartburn-relief-with-bicarbonate-rich-mineral-water-results-of-the-randomised-placebo-controlled-phase-iii-trial-stomach-still2023-03-29T10:06:56+02:00https://socratec-pharma.de/publications/the-global-bioequivalence-harmonisation-initiative-gbhi-report-of-the-fifth-international-eufeps-aaps-conference2023-08-28T19:26:20+02:00https://socratec-pharma.de/publications/summary-report-of-second-eufeps-aaps-conference-on-global-harmonization-in-bioequivalence2024-04-08T08:56:22+02:00https://socratec-pharma.de/publications/open-forum-conference-on-the-ich-m13a-bioequivalence-guideline2024-04-08T08:37:28+02:00https://socratec-pharma.de/publications/skin-adhesion-of-a-newly-developed-bioequivalent-rotigotine-patch-formulation-in-comparison-to-the-originator-product-results-of-a-multi-center-randomized-crossover-trial-in-patients-with-parkinso2024-11-28T13:57:28+01:00https://socratec-pharma.de/publications/new-ustekinumab-biosimilar-candidate-fyb202-pharmacokinetic-equivalence-demonstrated-in-a-randomized-double-blind-parallel-group-single-dose-trial-in-healthy-subjects2025-09-17T16:41:39+02:00https://socratec-pharma.de/publications/gastrointestinal-tolerability-of-d-allulose-in-adults-results-of-a-randomised-double-blind-placebo-controlled-trial2025-03-25T15:43:19+01:00https://socratec-pharma.de/publications/inhibition-of-ovulation-and-pharmacologic-mechanism-of-action-of-relugolix-combination-therapy2025-06-03T15:32:53+02:00https://socratec-pharma.de/publications/the-global-bioequivalence-harmonisation-initiative-gbhi-report-of-the-sixth-international-eufeps-pqri-conference2025-09-17T16:54:56+02:00